(NASDAQ: AGIO) Agios Pharmaceuticals's forecast annual revenue growth rate of 71.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Agios Pharmaceuticals's revenue in 2025 is $40,875,000.On average, 4 Wall Street analysts forecast AGIO's revenue for 2025 to be $2,514,749,902, with the lowest AGIO revenue forecast at $2,319,993,614, and the highest AGIO revenue forecast at $2,684,290,132. On average, 4 Wall Street analysts forecast AGIO's revenue for 2026 to be $5,448,586,053, with the lowest AGIO revenue forecast at $4,420,363,489, and the highest AGIO revenue forecast at $6,216,862,426.
In 2027, AGIO is forecast to generate $12,654,510,620 in revenue, with the lowest revenue forecast at $9,257,314,863 and the highest revenue forecast at $16,628,654,452.